Clinician's Roundtable   /     Poster Pearl: Comparing the Efficiency of Stool-Based CRC Screening Tests

Shownotes

Host: Matt Birnholz, MD

For patients at average risk of colorectal cancer (CRC), the United States Preventative Services Task Force recommends screening with either the multi-target stool DNA test or fecal immunochemical test. But in light of new performance data that compared a multi-target stool DNA test and a fecal immunochemical test, a poster presented at the 2024 Digestive Disease Week conference re-evaluated the benefits and harms associated with each test. Tune in to learn more about the findings and their implications for CRC screening.